MONA
MCID: MLT065
MIFTS: 40

Multicentric Osteolysis, Nodulosis, and Arthropathy (MONA)

Categories: Bone diseases, Fetal diseases, Genetic diseases, Rare diseases, Skin diseases

Aliases & Classifications for Multicentric Osteolysis, Nodulosis, and Arthropathy

MalaCards integrated aliases for Multicentric Osteolysis, Nodulosis, and Arthropathy:

Name: Multicentric Osteolysis, Nodulosis, and Arthropathy 56 25 73
Torg-Winchester Syndrome 24 52 25 73 13 71
Torg Syndrome 56 24 52 25 73 36
Nodulosis-Arthropathy-Osteolysis Syndrome 56 24 25 73
Nao Syndrome 56 25 73 54
Multicentric Osteolysis, Nodulosis and Arthropathy 52 29 6
Al-Aqeel Sewairi Syndrome 56 25 73
Mona 56 25 73
Hereditary Multicentric Osteolysis 25 73
Multicentric Osteolysis Nodulosis and Arthropathy 24
Nodulosis-Arthropathy-Osteolysis Syndrome, 52
Osteolysis, Hereditary Multicentric 56
Torg-Winchester Syndrome, Formerly 56
Torg Winchester Syndrome 39
Mona Syndrome 52

Characteristics:

OMIM:

56
Inheritance:
autosomal recessive

Miscellaneous:
abnormal gait


HPO:

31
multicentric osteolysis, nodulosis, and arthropathy:
Inheritance autosomal recessive inheritance
Onset and clinical course juvenile onset infantile onset


Classifications:



Summaries for Multicentric Osteolysis, Nodulosis, and Arthropathy

NIH Rare Diseases : 52 The following summary is from Orphanet , a European reference portal for information on rare diseases and orphan drugs. Orpha Number: 371428 Definition A rare systemic or rheumatologic disease characterized by peripheral osteolysis (especially carpal and tarsal bones), interphalangeal joint erosions, subcutaneous fibrocollagenous nodules, facial dysmorphism, and a wide range of associated manifestations. Epidemiology Multicentric osteolysis-nodulosis-arthropathy (MONA) spectrum prevalence and incidence of MONA are not known. Fewer than 50 cases have been reported worldwide. Cases have been reported from Saudi Arabia, Italy, Turkey, Algeria, Morocco, the United States, and Korea. Clinical description Onset is usually at preschool age (1-5 years) and the course of the disease is variable. Manifestations of the disorder include multiple peripheral osteolysis beginning at the carpal, tarsal, metacarpal/metatarsal-phalangeal and interphalangeal joints with subsequent generalization. The joint erosions lead to small hands and feet, arthropathy causing decreased range of motion, and progressive joint contractures . Some patients have been reported to have wide metacarpals and metatarsals, generalized osteoporosis of vertebrae, short stature , coarse face or facial dysmorphism (frontal bossing and hypertelorism), gum hypertrophy, corneal opacities, hyperpigmentation, hypertrichosis, and subcutaneous fibrocollagenous nodules. Associated cardiac malformations have been reported and included transposition of the great arteries, mitral valve prolapse, bicuspid aortic valve, and atrial and ventricular septal defects. Intrafamilial variability of manifestations is also found. Due to overlapping clinical features and the involvement of mutations in MMP2 gene , Torg-Winchester syndrome and nodulosis-arthropathy-osteolysis (NAO) syndromes, that were originally reported separately, are now presumed to belong to the clinical spectrum of MONA (with other nomenclatures still being is use). Etiology MONA spectrum disorders are caused by mutations in the MMP2 gene (16q13-q21) or MMP14 gene (14q11-q12). The pathogenesis of the disorder remains unclear. Diagnostic methods The diagnosis is based on the clinical manifestations of the disease and can be confirmed by molecular genetic testing . Differential diagnosis The main differential diagnoses are juvenile idiopathic arthritis and multicentric carpotarsal osteolysis. Genetic counseling MONA spectrum disorders follow an autosomal recessive pattern on inheritance. Many cases are reported in children from consanguineous unions. Genetic counseling should be proposed to individuals having the disease-causing mutation informing them that there is 25% risk of passing the mutation to offspring. Management and treatment There is no specific treatment for MONA spectrum. Management is primarily symptomatic. Some patients initially respond to non-steroidal anti-inflammatory drugs (NSAIDs). Prognosis The progressive joint destruction leads to significant disability; many patients are wheelchair bound. However, life expectancy does not appear to be significantly affected. Visit the Orphanet disease page for more resources.

MalaCards based summary : Multicentric Osteolysis, Nodulosis, and Arthropathy, also known as torg-winchester syndrome, is related to multicentric osteolysis-nodulosis-arthropathy spectrum and winchester syndrome. An important gene associated with Multicentric Osteolysis, Nodulosis, and Arthropathy is MMP2 (Matrix Metallopeptidase 2). The drugs Clobetasol and Copper have been mentioned in the context of this disorder. Affiliated tissues include bone, skin and testes, and related phenotypes are hypertelorism and frontal bossing

Genetics Home Reference : 25 Multicentric osteolysis, nodulosis, and arthropathy (MONA) describes a rare inherited disease characterized by a loss of bone tissue (osteolysis), particularly in the hands and feet. MONA includes a condition formerly called nodulosis-arthropathy-osteolysis (NAO) syndrome. It may also include a similar disorder called Torg syndrome, although it is unknown whether Torg syndrome is actually part of MONA or a separate disorder caused by a mutation in a different gene. In most cases of MONA, bone loss begins in the hands and feet, causing pain and limiting movement. Bone abnormalities can later spread to other areas of the body, with joint problems (arthropathy) occurring in the elbows, shoulders, knees, hips, and spine. Most people with MONA develop low bone mineral density (osteopenia) and thinning of the bones (osteoporosis) throughout the skeleton. These abnormalities make bones brittle and more prone to fracture. The bone abnormalities also lead to short stature. Many affected individuals develop subcutaneous nodules, which are firm lumps of noncancerous tissue underneath the skin, especially on the soles of the feet. Some affected individuals also have skin abnormalities including patches of dark, thick, and leathery skin. Other features of MONA can include clouding of the clear front covering of the eye (corneal opacity), excess hair growth (hypertrichosis), overgrowth of the gums, heart abnormalities, and distinctive facial features that are described as "coarse."

OMIM : 56 Zankl et al. (2007) defined what they considered to be a continuous clinical spectrum involving Torg syndrome, Winchester syndrome (277950), and NAO syndrome. Torg syndrome is characterized by the presence of multiple, painless, subcutaneous nodules and mild to moderate osteoporosis and osteolysis that is usually limited to the hands and feet. Radiographically, the osteolysis is accompanied by a characteristic widening of the metacarpal and metatarsal bones. Winchester syndrome presents with severe osteolysis in the hands and feet and generalized osteoporosis and bone thinning, similar to NAO, but subcutaneous nodules are characteristically absent. Various additional features including coarse face, corneal opacities, gum hypertrophy, and EKG changes have been reported. NAO syndrome, which has only been described in patients from Saudi Arabia, is generally more severe, with multiple prominent and painful subcutaneous nodules, massive osteolysis in the hands and feet, and generalized osteoporosis. Coarse face and body hirsutism are additional features. (259600)

KEGG : 36 Torg syndrome, also known as Multicentric osteolysis, nodulosis, and arthropathy (MONA) is a multicentric osteolysis syndrome characterized by progressive bone loss in hands and feet. MMP2 mutations are reported in patients with Torg-Winchester syndrome.

UniProtKB/Swiss-Prot : 73 Multicentric osteolysis, nodulosis, and arthropathy: An autosomal recessive syndrome characterized by severe multicentric osteolysis with predominant involvement of the hands and feet. Additional features include coarse face, corneal opacities, patches of thickened, hyperpigmented skin, hypertrichosis and gum hypertrophy.

GeneReviews: NBK373578

Related Diseases for Multicentric Osteolysis, Nodulosis, and Arthropathy

Diseases in the Multicentric Osteolysis, Nodulosis, and Arthropathy family:

Multicentric Osteolysis-Nodulosis-Arthropathy Spectrum

Diseases related to Multicentric Osteolysis, Nodulosis, and Arthropathy via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 13)
# Related Disease Score Top Affiliating Genes
1 multicentric osteolysis-nodulosis-arthropathy spectrum 29.3 MMP2 LPCAT2
2 winchester syndrome 12.0
3 multicentric carpotarsal osteolysis syndrome 11.6
4 arthropathy 10.8
5 autosomal recessive disease 10.7
6 osteoporosis 10.4
7 bone mineral density quantitative trait locus 8 10.4
8 bone mineral density quantitative trait locus 15 10.4
9 ankylosis 10.3
10 systemic scleroderma 10.3
11 exophthalmos 10.3
12 juvenile rheumatoid arthritis 10.0
13 headache 10.0

Graphical network of the top 20 diseases related to Multicentric Osteolysis, Nodulosis, and Arthropathy:



Diseases related to Multicentric Osteolysis, Nodulosis, and Arthropathy

Symptoms & Phenotypes for Multicentric Osteolysis, Nodulosis, and Arthropathy

Human phenotypes related to Multicentric Osteolysis, Nodulosis, and Arthropathy:

31 (show top 50) (show all 51)
# Description HPO Frequency HPO Source Accession
1 hypertelorism 31 HP:0000316
2 frontal bossing 31 HP:0002007
3 gait disturbance 31 HP:0001288
4 osteopenia 31 HP:0000938
5 coarse facial features 31 HP:0000280
6 gingival overgrowth 31 HP:0000212
7 pes planus 31 HP:0001763
8 short stature 31 HP:0004322
9 micrognathia 31 HP:0000347
10 osteoporosis 31 HP:0000939
11 subcutaneous nodule 31 HP:0001482
12 arthralgia 31 HP:0002829
13 brachycephaly 31 HP:0000248
14 narrow nasal bridge 31 HP:0000446
15 hypermelanotic macule 31 HP:0001034
16 delayed eruption of teeth 31 HP:0000684
17 abnormality of the thorax 31 HP:0000765
18 thickened skin 31 HP:0001072
19 pes cavus 31 HP:0001761
20 kyphoscoliosis 31 HP:0002751
21 proptosis 31 HP:0000520
22 hypoplasia of the maxilla 31 HP:0000327
23 protrusio acetabuli 31 HP:0003179
24 bulbous nose 31 HP:0000414
25 split hand 31 HP:0001171
26 wrist flexion contracture 31 HP:0001239
27 hip contracture 31 HP:0003273
28 abnormality of the ear 31 HP:0000598
29 antinuclear antibody positivity 31 HP:0003493
30 hirsutism 31 HP:0001007
31 camptodactyly of toe 31 HP:0001836
32 broad metatarsal 31 HP:0001783
33 vertebral compression fractures 31 HP:0002953
34 thin metacarpal cortices 31 HP:0006086
35 thin metatarsal cortices 31 HP:0008078
36 delayed closure of the anterior fontanelle 31 HP:0001476
37 carpal osteolysis 31 HP:0001495
38 metacarpal osteolysis 31 HP:0001504
39 metaphyseal widening 31 HP:0003016
40 osteolysis involving tarsal bones 31 HP:0006234
41 sclerotic cranial sutures 31 HP:0005441
42 finger swelling 31 HP:0025131
43 ankle flexion contracture 31 HP:0006466
44 metatarsal osteolysis 31 HP:0001473
45 c1-c2 subluxation 31 HP:0003320
46 interphalangeal joint contracture of finger 31 HP:0001220
47 widened metacarpal shaft 31 HP:0006012
48 interphalangeal joint erosions 31 HP:0006252
49 peripheral opacification of the cornea 31 HP:0008011
50 ankylosis of feet small joints 31 HP:0008090

Symptoms via clinical synopsis from OMIM:

56
Skeletal Feet:
pes planus
pes cavus
thin metatarsal cortices
interphalangeal joint erosions
tarsal osteolysis
more
Skeletal Hands:
thin metacarpal cortices
carpal osteolysis
widened metacarpal shaft
interphalangeal joint erosions
finger contractures
more
Skeletal Limbs:
flexion contractures (elbows and knees)

Laboratory Abnormalities:
elevated antinuclear antibody (ana) (speckled pattern)
elevated il1-beta
elevated il6

Skeletal:
osteoporosis

Skeletal Pelvis:
flexion contracture (hip)

Skin Nails Hair Skin:
subcutaneous nodules (interphalangeal joints, knees, feet, elbows, pretibial)
hyperpigmented erythematous lesions

Clinical features from OMIM:

259600

Drugs & Therapeutics for Multicentric Osteolysis, Nodulosis, and Arthropathy

Drugs for Multicentric Osteolysis, Nodulosis, and Arthropathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 24)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Clobetasol Approved, Experimental, Investigational Phase 3 25122-46-7, 25122-41-2 32798 5311051
2
Copper Approved, Investigational Phase 3 7440-50-8 27099
3 Anti-Inflammatory Agents Phase 3
4 Hormone Antagonists Phase 3
5 Hormones Phase 3
6 glucocorticoids Phase 3
7 Nutrients Phase 3
8 Trace Elements Phase 3
9 Micronutrients Phase 3
10
Pamidronate Approved 40391-99-9 4674
11
Zoledronic Acid Approved 118072-93-8 68740
12
tannic acid Approved 1401-55-4
13
Heparin Approved, Investigational 9005-49-6 772 46507594
14
Benzocaine Approved, Investigational 1994-09-7, 94-09-7 2337
15
Propofol Approved, Investigational, Vet_approved 2078-54-8 4943
16 Diphosphonates
17 Hemostatics
18 Dermatologic Agents
19 Anesthetics
20 calcium heparin
21 Hypnotics and Sedatives
22 Anesthetics, General
23 Central Nervous System Depressants
24 Anesthetics, Intravenous

Interventional clinical trials:

(show all 17)
# Name Status NCT ID Phase Drugs
1 A Randomized Trial of Clobetasol Proprionate Versus Fractionated CO2 Laser for the Treatment of Lichen Sclerosus (CuRLS) Completed NCT02573883 Phase 3 Clobetasol Propionate 0.05% ointment
2 A Multi-center, Single-blind, Randomized Clinical Trial to Compare Two Copper IUDs: Mona Lisa NT Cu380 Mini and ParaGard Active, not recruiting NCT03124160 Phase 3 Mona Lisa® NT Cu380 Mini;ParaGard® CuT380A
3 Prevention of Catheter Associated Lower Urinary Infections Using the Oxys Indwelling Catheter Unknown status NCT02658903 Phase 1
4 Bisphosphonates in Multicentric Osteolysis, Nodulosis and Arthropathy (MONA) Spectrum Disorder - an Alternative Therapeutic Approach Completed NCT02823925 Pamidronate or Zoledronate
5 Valiant Mona LSA Stent Graft System Early Feasibility Study Completed NCT01839695
6 A Comparison of a Dance Programme Delivered With the XBOX Kinect With Traditional Agility Ladder Drills on Agility Scores of Club Level Volleyball Players of the University of the West Indies, Mona Completed NCT02370368
7 Dietary Restrictions Implications on Metabolic Changes in Obese Men : Comparison Between Two Groups of Different Ages (60-70 Years Old Versus 30-40 Years Old) Completed NCT02161926
8 The Impact of Comorbidity and Which Type of Comorbidity That is Most Important to Predict Readmission to Intensive Care and Mortality of Intensive Care Patients Completed NCT04109001
9 Development and Testing of a Jamaican Mother-daughter HIV Risk-reduction Program Completed NCT03411577
10 Prospective Population Based Cohort Study on Cognitive and Cardiovascular Aging Recruiting NCT02566538
11 A Randomized, Placebo-Controlled Trial Evaluating Radiofrequency and Hybrid Fractional Laser for Vaginal Rejuvenation Recruiting NCT03316950
12 International Bicuspid Aortic Valve Consortium (BAVCon) Recruiting NCT01980797
13 Evaluation of the Valiant Mona LSA Thoracic Stent Graft System in Descending Thoracic Aortic Aneurysms and Chronic Dissections Active, not recruiting NCT02365467
14 Evaluation of the Valiant Mona LSA Thoracic Stent Graft System in Thoracic Aortic Aneurysms and Chronic Dissections Not yet recruiting NCT03738124
15 Back Pain in Preclinical and Clinical Medical Students at The University of the West Indies, Mona, Jamaica Not yet recruiting NCT03707288
16 English Title: Extreme Challenges - Psychopathology, Treatment Organization and Experiences Among Psychiatric Inpatients With Severe Self-harming Behavior in Norway Not yet recruiting NCT03768674
17 Vibration Analgesia in Propofol Infusion During Anesthesia Induction Not yet recruiting NCT03509857

Search NIH Clinical Center for Multicentric Osteolysis, Nodulosis, and Arthropathy

Genetic Tests for Multicentric Osteolysis, Nodulosis, and Arthropathy

Genetic tests related to Multicentric Osteolysis, Nodulosis, and Arthropathy:

# Genetic test Affiliating Genes
1 Multicentric Osteolysis, Nodulosis and Arthropathy 29 MMP2

Anatomical Context for Multicentric Osteolysis, Nodulosis, and Arthropathy

MalaCards organs/tissues related to Multicentric Osteolysis, Nodulosis, and Arthropathy:

40
Bone, Skin, Testes, Eye, Heart

Publications for Multicentric Osteolysis, Nodulosis, and Arthropathy

Articles related to Multicentric Osteolysis, Nodulosis, and Arthropathy:

(show all 37)
# Title Authors PMID Year
1
Torg syndrome is caused by inactivating mutations in MMP2 and is allelic to NAO and Winchester syndrome. 61 24 56 6
17059372 2007
2
A novel homozygous MMP2 mutation in a family with Winchester syndrome. 54 24 56 6
16542393 2006
3
Winchester syndrome caused by a homozygous mutation affecting the active site of matrix metalloproteinase 2. 24 56 6
15691365 2005
4
Mutation of the matrix metalloproteinase 2 gene (MMP2) causes a multicentric osteolysis and arthritis syndrome. 24 56 6
11431697 2001
5
[Biochemical and ultrastructural study of two familial cases of Winchester syndrome]. 56 6
2625626 1989
6
Mutation of membrane type-1 metalloproteinase, MT1-MMP, causes the multicentric osteolysis and arthritis disease Winchester syndrome. 24 56
22922033 2012
7
Loss of MMP-2 disrupts skeletal and craniofacial development and results in decreased bone mineralization, joint erosion and defects in osteoblast and osteoclast growth. 24 56
17400654 2007
8
New form of idiopathic osteolysis: nodulosis, arthropathy and osteolysis (NAO) syndrome. 24 56
10861675 2000
9
Multicentric Osteolysis Nodulosis and Arthropathy 61 6
27413800 2016
10
Al-Aqeel Sewairi syndrome, a new autosomal recessive disorder with multicentric osteolysis, nodulosis and arthropathy. The first genetic defect of matrix metalloproteinase 2 gene. 61 56
15756348 2005
11
Clinical and mutation profile of multicentric osteolysis nodulosis and arthropathy. 61 24
26601801 2016
12
Functional characterisation of a novel mutation affecting the catalytic domain of MMP2 in siblings with multicentric osteolysis, nodulosis and arthropathy. 61 24
25273674 2014
13
A report of three patients with MMP2 associated hereditary osteolysis. 61 24
22876575 2012
14
A novel homozygous MMP2 mutation in a patient with Torg-Winchester syndrome. 61 24
20720557 2010
15
Clinical and radiographic findings in two brothers affected with a novel mutation in matrix metalloproteinase 2 gene. 61 24
19653001 2010
16
Torg-Winchester syndrome: lack of efficacy of pamidronate therapy. 61 24
17351352 2007
17
Nosology and classification of genetic skeletal disorders: 2006 revision. 56
17120245 2007
18
Inherited multicentric osteolysis with arthritis: a variant resembling Torg syndrome in a Saudi family. 56
10861676 2000
19
Structure of human pro-matrix metalloproteinase-2: activation mechanism revealed. 6
10356396 1999
20
Torg osteolysis syndrome. 56
9843039 1998
21
An interactive computer graphics study of thermolysin-catalyzed peptide cleavage and inhibition by N-carboxymethyl dipeptides. 6
6525336 1984
22
[Familial multicentric osteolysis with recessive transmission. Four cases in a family (author's transl)]. 56
7325547 1981
23
Hereditary multicentric osteolysis with recessive transmission: a new syndrome. 56
5795345 1969
24
A new acid mucopolysaccharidosis with skeletal deformities simulating rheumatoid arthritis. 56
4238825 1969
25
Mutation in MMP2 gene may result in scleroderma-like skin thickening. 24
26420579 2016
26
Patient with mutation in the matrix metalloproteinase 2 (MMP2) gene - a case report and review of the literature. 24
24637309 2014
27
Multicentric osteolysis with nodulosis and arthropathy (MONA) with cardiac malformation, mimicking polyarticular juvenile idiopathic arthritis: case report and literature review. 24
23900523 2013
28
A novel matrix metalloproteinase 2 (MMP2) terminal hemopexin domain mutation in a family with multicentric osteolysis with nodulosis and arthritis with cardiac defects. 24
18985071 2009
29
Multicentric osteolytic syndromes represent a phenotypic spectrum defined by defective collagen remodeling. 61
31218820 2019
30
A novel mutation in the matrix metallopeptidase 2 coding gene associated with intrafamilial variability of multicentric osteolysis, nodulosis, and arthropathy. 61
31268248 2019
31
Characterization of Normal Murine Carpal Bone Development Prompts Re-Evaluation of Pathologic Osteolysis as the Cause of Human Carpal-Tarsal Osteolysis Disorders. 61
28675805 2017
32
Bisphosphonates in multicentric osteolysis, nodulosis and arthropathy (MONA) spectrum disorder - an alternative therapeutic approach. 61
27687687 2016
33
Identification of drug-target interaction from interactome network with 'guilt-by-association' principle and topology features. 61
26614126 2016
34
A novel fibrotic disorder associated with increased dermal fibroblast proliferation and downregulation of genes of the microfibrillar network. 61
20560960 2010
35
Absence of MMP2 mutation in idiopathic multicentric osteolysis with nephropathy. 54
17563705 2007
36
The new syndrome is not really a new syndrome. Al-Aqeel Sewairi syndrome, a new autosomal recessive disorder with multicentric osteolysis, nodulosis, and arthropathy. 61
16047082 2005
37
The new syndrome is not really a new syndrome. Al-Aqeel Sewairi syndrome, a new autosomal recessive disorder with multicentric osteolysis, nodulosis, and arthropathy. 61
16178093 2005

Variations for Multicentric Osteolysis, Nodulosis, and Arthropathy

ClinVar genetic disease variations for Multicentric Osteolysis, Nodulosis, and Arthropathy:

6 ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 MMP2 NM_004530.6(MMP2):c.302G>A (p.Arg101His)SNV Pathogenic 17108 rs121912953 16:55516969-55516969 16:55483057-55483057
2 MMP2 NM_004530.6(MMP2):c.732C>A (p.Tyr244Ter)SNV Pathogenic 17109 rs121912954 16:55519589-55519589 16:55485677-55485677
3 MMP2 NM_004530.6(MMP2):c.1210G>A (p.Glu404Lys)SNV Pathogenic 17110 rs121912955 16:55525742-55525742 16:55491830-55491830
4 MMP2 MMP2, 3-BP DEL, 1488TGGdeletion Pathogenic 17111
5 MMP2 NM_004530.6(MMP2):c.1357del (p.Gly454fs)deletion Pathogenic 17112 rs1567378779 16:55527089-55527089 16:55493177-55493177
6 LPCAT2 NM_017839.5(LPCAT2):c.172-6188G>ASNV Pathogenic 625853 rs1567390809 16:55553232-55553232 16:55519320-55519320
7 MMP2 NM_004530.6(MMP2):c.377A>G (p.Tyr126Cys)SNV Uncertain significance 690375 16:55517044-55517044 16:55483132-55483132
8 MMP2 NM_004530.6(MMP2):c.539A>T (p.Asp180Val)SNV Uncertain significance 374345 rs1057518712 16:55519220-55519220 16:55485308-55485308

UniProtKB/Swiss-Prot genetic disease variations for Multicentric Osteolysis, Nodulosis, and Arthropathy:

73
# Symbol AA change Variation ID SNP ID
1 MMP2 p.Arg101His VAR_032423 rs121912953
2 MMP2 p.Glu404Lys VAR_032425 rs121912955

Expression for Multicentric Osteolysis, Nodulosis, and Arthropathy

Search GEO for disease gene expression data for Multicentric Osteolysis, Nodulosis, and Arthropathy.

Pathways for Multicentric Osteolysis, Nodulosis, and Arthropathy

GO Terms for Multicentric Osteolysis, Nodulosis, and Arthropathy

Sources for Multicentric Osteolysis, Nodulosis, and Arthropathy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....